Rnable

RNAble is a preclinical biotechnology company developing a potent small-molecule inhibitor targeting FTO, a key driver of oncogenic RNA biology. Mechanistic studies have led to the identification of a specific biomarker that predicts pan-cancer sensitivity to the inhibitor across both hematological and solid malignancies. Key highlights of RNAble's lead candidate: • Demonstrates strong in vivo efficacy and superior antitumor activity compared to standard-of-care therapies in AML models. • Shows promising efficacy in preclinical models of biomarker-selected solid tumors. • Features a novel, validated mechanism of action that induces cancer cell death via RNA-mediated mitotic catastrophe followed by apoptosis, with potential to overcome resistance to current therapies. • Exhibits strong oral bioavailability and a favorable safety profile. • Expected IND submission in 2026.